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Available online 4 June 2016Malignant peripheral nerve sheath tumors (MPNST) are rare soft tissue sarcomas that are amajor source ofmor-
tality in neuroﬁbromatosis type 1 (NF1) patients. To identifyMPNST driver genes, we performed a lentiviral short
hairpin (sh) RNA screen, targeting all 130 genes up-regulated in neuroﬁbroma and MPNSTs versus normal
human nerve Schwann cells. NF1mutant cells show activation of RAS/MAPK signaling, so a counter-screen in
RAS mutant carcinoma cells was performed to exclude common RAS-pathway driven genes. We identiﬁed 7
genes speciﬁc for survival of MPSNT cells, includingMEIS1.MEIS1 was frequently ampliﬁed or hypomethylated
in human MPSNTs, correlating with elevated MEIS1 gene expression. In MPNST cells and in a genetically
engineered mouse model, MEIS1 expression in developing nerve glial cells was necessary for MPNST growth.
Mechanistically,MEIS1 drivesMPNST cell growth via the transcription factor ID1, thereby suppressing expression
of the cell cycle inhibitor p27Kip and maintaining cell survival.
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Sarcoma1. Introduction
Identiﬁcation of the genes that drive carcinogenesis is essential to
understandmechanisms that underlie tumor emergence and evolution,
and to formulation of effective therapeutic strategies. This need is espe-
cially critical in sarcomas, because most are poorly characterized and
lack effective therapies. Malignant peripheral nerve sheath tumors
(MPNSTs) are aggressive soft tissue sarcomas that occur sporadically
or, in half of the cases occur in association with neuroﬁbromatosis
type 1 (NF1) (Ducatman et al., 1986; Widemann, 2009). This genetic
link led to the understanding that MPNST in NF1 patients have biallelic
NF1mutations (Bottillo et al., 2009; Legius et al., 1993). This results in
RAS pathway activation because the NF1 gene product, neuroﬁbromin,
binds to RAS proteins and accelerates their intrinsic GTPase activity
(Bos et al., 2007). Further, sporadicMPNST also showNF1 loss or activat-
ing RAS or RAF mutations (Ratner and Miller, 2015). In spite of this
understanding, the current treatment for MPNST patients remains
surgical resection of the tumor, followed by non-speciﬁc high-doseematology and Cancer Biology,
e, M.L.C. 7013, Cincinnati, OH
pen access article under the CC BY-Nchemotherapy (Gregorian et al., 2009; Katz et al., 2009). Unfortunately,
without complete tumor resection MPNST are resistant to this thera-
peutic approach and fewer than 25% patients survive 5-years after diag-
nosis (Katz et al., 2009; Widemann, 2009).
MPNST cells, like many sarcomas, show complex hyperdiploid kar-
yotypes, but most genetic changes that drive transformation are un-
known. Importantly, when the MPNST precursor lesion called the
atypical neuroﬁbromadevelops in anNF1 patient, the tumor suppressor
gene CDKN2A is mutant or lost (Legius et al., 1993; Nielsen et al., 1999).
An MPNST mouse model (GEM-PNST) mimics this combination of mu-
tations. Consistent with a critical role for loss of the CDKN2A locus in
driving MPSNT, 26% of Nf1+/−;Ink4a/Arf−/−mice form GEM-PNST
(Joseph et al., 2008). In addition, mutations in epigenetic modiﬁer
genes of the PRC2 complex occur in many human MPNST. Functional
data suggest that these mutations are under positive selection pressure
(De Raedt et al., 2014; Lee et al., 2014). Human MPNST show inconsis-
tent loss of function mutation in other tumor suppressor genes that in-
hibit the cell cycle, such as TP53 and RB (Legius et al., 1994). A more
complete understanding of the molecular mechanisms that drive
MPNST is necessary to facilitate development of new targeted therapies.
Lineage dependence, sometimes called lineage addiction, can identi-
fy genes that are important cancer targets (Garraway and Sellers, 2006).
Gene expression proﬁlingmay thus demonstrate an enrichment of such
genes, if overexpressed genes reﬂect the lineage of the tumor cells.C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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transcriptional analysis to deﬁne oncogenes to which leukemias are
addicted (Zuber et al., 2011a, 2011b). To identify MPNST drivers, we
used available transcriptome data (Miller et al., 2009). Human neuroﬁ-
broma and MPNST gene expression proﬁles were compared to those of
normal human Schwann cells, because Schwann cells and/or their neu-
ral crest cell precursor like cells are believed to be the pathogenic drivers
of MPNST (Buchstaller et al., 2012; Vogel et al., 1999). Analysis of this
genome wide data set previously identiﬁed neural crest genes as abun-
dantly expressed in human MPNSTs, and established that MPNST cells
in vitro could be killed by inhibition of the SOX9 lineage gene (Miller
et al., 2009). We hypothesized that other overexpressed genes could
be identiﬁed among the overexpressed genes and necessary for
MPNST cell growth and tumor maintenance.
We used RNA interference (RNAi), a common approach to inhibit
gene expression, inwhichbinding of sequence-speciﬁc small interfering
(siRNA) targets transcript cleavage, resulting in transcript degradation
(Rana, 2007). RNAi screening combines the power of genetic screens
with phenotypic assays in vitro, making it possible to identify genes in-
volved in a wide variety of biological processes, including identiﬁcation
of oncogenic drivers (Bernards et al., 2006; Zhuang and Hunter, 2012;
Boutros and Ahringer, 2008; Zhuang and Hunter, 2012). Although
RNAi technology has been used for more than a decade, large scale
RNAi screens have not been reported in MPNST. We generated a
lentiviral shRNA library to inhibit 130 genes identiﬁed as overexpressed
in human neuroﬁbroma and MPNSTs versus normal human Schwann
cells. By screening this custom shRNA library, we identify the protein
MEIS1 as being critically required for MPNST tumorogenesis.
MEIS1 encodes a homeobox protein belonging to the three amino
acid loop extension (TALE) family of homeodomain-containing pro-
teins. XMeis1 speciﬁes neural crest identity in the frog embryo (Maeda
et al., 2001), butMEIS1 has not been studied in mouse or human neural
crest in detail. Mice lackingMeis1 do not show obvious neural crest de-
fect, but rather show major defects in retina, lens morphogenesis, he-
matopoietic cells and vasculature, and die by embryonic day 14.5
(Hisa et al., 2004). During hematopoiesis, Meis1 expression levels are
highest in self-renewing hematopoietic stem cells (HSCs) and decline
with cell differentiation (Pineault et al., 2002; Chen et al., 2008). The
Meis1 gene is a common target of retroviral insertion in amurine leuke-
mia model andMeis1 overexpression in hematopoietic cells causes ag-
gressive leukemia in mice, deﬁningMeis1 as an oncogene (Nakamura
et al., 1996; Thorsteinsdottir et al., 2001). MEIS1 is also frequently
overexpressed and ampliﬁed in human neuroblastoma, a tumor of neu-
ral crest derived cells (Spieker et al., 2001). How Meis1 acts in any
tumor type is unclear. Indeed,Meis1 regulated genes show little overlap
in diverse systems, and target regulation is likely to be complex
(Dardaei et al., 2015). Our results establish MEIS1 as a driver of
MPNST cell growth, which acts on the cell cycle through ID1 and inhibi-
tion of p27Kip.
2. Experimental procedures
2.1. Tumor samples
Human MPNST were collected in accordance with institutional re-
view board-approved protocols from discarded surgical specimens,
and were received from the Cincinnati Children's Hospital Bio Bank as
ﬂash frozen or parafﬁn embedded samples.
2.2. Cell lines and reagents
MPNST cell lines STS26T (sporadic; NF1 wild type;
RRID:CVCL_8917), and 8814 (RRID:CVCL_8916), 88-3, S462TY
(RRID:CVCL_1Y70), T265 (RRID:CVCL_S805; all NF1mutant), and im-
mortalized human Schwann cells (iHSC) (Rahrmann et al., 2013), and
normal human Schwann cells (NHSC) from autopsy specimens wereobtained and maintained as described in (Miller et al., 2006; Watson
et al., 2013; Declue et al., 1992).
2.3. Lentiviral transduction
MPNST cells were transduced with lentiviral particles at 50–60%
conﬂuence. Short hairpins (sh) RNAs targeting gene of interest and con-
trol non-targeting construct were from the Sigma Aldrich TRC library.
The CCHMC Viral Vector Core produced virus using a 4-plasmid packag-
ing system (http://www.cincinnatichildrens.org/research/div/
exphematology/translational/vpf/vvc/default. html). Lentiviral particles
were incubated with MPNST cells in the presence of polybrene (8 μg/
mL; Sigma) for 24 h, followed by selection in 2 μg/mL puromycin,
which killed uninfected cells within 3 days.
2.4. Lentiviral shRNA screening
MPNST cells plated on day (−1) at 1000 cell/well in 96 well plates.
Once the cells successfully adhered to the plate (4 h post plating), cell
were transduced with lentiviral shRNA. Puromycin is added on day (0)
to select for cells successfully infected with the virus. Growth was mea-
sured onDay 5 using ametabolic assay (CellTiter 96®AQueous One Solu-
tion Cell Proliferation Assay, Promega #G3582), measured as absorbance
at 490 nm. Controls include - 1) lenti-virus encoding shSOX9 - positive
control for death 2) non-targeting shRNA - negative control. shSOX9
treated MPNST cells show signiﬁcant detrimental effect on survival by
end point, thus this is used as a bench mark for an effect on cell growth.
Screen I was conducted on only one MPNST cell line the T265 which are
null for the NF1 gene. Screen II was conducted exactly as Screen I but
with the addition of 8814, STS26T (sporadic MPNST cell line, wild type
for NF1) and 88-3 MPNST cell lines. Screen III used 127shRNAs targeting
genes of interest for analysis of growth for MPNST (T265) versus a lung
adenocarcinoma cell line (A549) (dot plot, Fig. 1D).
2.5. Immunoblot
We washed cells with ice-cold PBS, lysed them in RIPA buffer, and
boiled lysates for 5 min. Lysates were analyzed immediately or frozen
at −20 °C. Proteins were separated on 4–20% denaturing SDS-PAGE
gradient gels (Bio-Rad#456-1094) and transferred to PVDFmembranes
(Millipore; Billerica, MA #IPFL00010). The membranes were blocked
with 5% milk in 0.1 M Tris-buffered saline with 0.1% Tween (TBST), in-
cubated with primary and secondary antibodies, and washed following
manufacturer's instructions. Secondary antibodies were detected by
chemi-luminescence (Millipore cat. #WBKLS0500). Primary antibodies
were anti-MEIS1 (Abcam #ab19867, RRID: AB_776272), anti-cleaved
PARP (Cell Signaling Technology Inc.) (CST; #9541, RRID: AB_331427),
p27Kip (CST; #3686, RRID: AB_2077850), Phospho-Rb (Ser795) (CST
#9301, RRID: AB_330013), Phospho-Rb (Ser807/811) (CST; 8516,
RRID: AB_11178658) and ID1 (Abcam; #ab134163, RRID: AB_
2572295). Anti-cyclin antibodies were from the cyclin sampler kit
(CST; #9869, RRID: AB_1903944). Anti-rabbit IgG, HRP-linked (CST;
#7074, RRID: AB_2099233) or anti-mouse IgG, HRP-linked (CST;
#7076, RRID: AB_330924) were used appropriately depending on the
host of the primary antibody. All membranes were stripped with strip-
ping buffer for 5 min (Fisher #21059) to re-probe with HRP conjugated
anti-β-actin (CST, #5125, RRID: AB_1903890) as a loading control.
2.6. Quantitative real time PCR (QRT)-PCR
Total cellular RNAwas isolatedwith the RNeasy kit (Qiagen) and used
as a template for cDNA synthesis (High-Capacity cDNA archive kit, Ap-
plied Biosystems) and QRT-PCR (ABI 7500 Sequence Detection System)
as described (Patel et al., 2012). Primers were purchased as pre-validated
qPCR sets from Integrated DNA Technologies. All qRT-PCR reactions were
conducted multiple times with three or more replicates per experiment.
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Tumors were dissected and ﬁxed overnight in 10% formalin then
cleared in 70% ethanol, dehydrated, and embedded in parafﬁn (http://
www.cincinnatichildrens.org/research/cores/pathology-core/default/).
Hematoxylin and eosin (H&E) and immunoperoxidase staining of 5 μm
parafﬁn sections followed standard protocols. Antibodies used were
rabbit anti-S100 (1:5000, DAKO; Z0311, RRID: AB_10013383) and rab-
bit anti-MEIS1 (1:1000 Abcam; #ab19867, RRID: AB_776272). For nu-
clear staining, sections were incubated in DAPI (SIGMA, 1:10,000) for
5 min, rinsed in 1X PBS thrice, and cover slipped in Flouromount G
(EM Sciences, #17984-25, RRID: AB_2572296). Sections were
photographed on a Nikon eclipse 80i bright ﬁeld microscope.
2.8. Cell cycle and viability analysis
We transduced 2 × 105 MPNST cells with shMEIS1 or vector control.
Cells were stainedwith propidium iodide and annexin V-alexaﬂuor 647
conjugate according to manufacturer's instructions (Life Technologies,
Grand Island, NY, USA #A23204). Flow cytometry was performed on a
FACSCanto (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed
using FlowJo software.
2.9. shRNA growth assays
We plated MPNST cells on day (−1) at 1000 cell/well in 96 well
plates. Once cells adhered to the plate (5 h post plating) theywere incu-
bated with lentiviral shRNA for 24 h. Puromycin (2 μg/mL) was added
on day (0) to select for cells infected with the virus. MTS reagent
(CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega
#G3582) or Alamar blue (Life Technologies, #88951)was added at end-
point and growth measured as absorbance intensity per manufacturer
instructions.
2.10. MPNST rescue experiment
MouseMeis1 cDNAwas (Addgene #21013)was cloned fromMSCV-
IRES-YFP into pCDH-RFP a lentivirus-compatible plasmid vector. The
pCDH-Meis1-RFP was packaged into a lentivirus by the CCHMC viral
vector core (https://research.cchmc.org/translationalcores/vector-
production/pre-clinical-and-research-vector-products). MPNST cells
were co-infected with shMEIS1 and pCDH-Meis1-RFP lentiviral parti-
cles at 60–70% conﬂuence. Controls included co-infection of each
shMEIS1 and pCDH-Meis1-RFP with shNon-targeting (shNT). For each
condition, we split cells into three for cell survival in 96 well plates
MTS assays and protein and RNA for further analysis.
2.11. Animal studies
Mice were housed in temperature and humidity controlled facilities
with free access to food andwater, on a 12-h dark–light cycle. The animal
care and use committee of Cincinnati Children's Hospital Medical Center
approved all animal use. Ink4a/Arf−/− mice were originally from the
B6.129-Cdkn2atm1Rdp NCI; Mouse repository MMHCC strain #01XB1
(RRID:IMRS_NCIMR:01XB1). Theywere back crossed to pure C57BL/6J fe-
males for 5 generations before breeding for the compound mutant mice.
Other mouse lines used are Nf1+/− (Brannan et al., 1994), and Meis1f/f
(Unnisa et al., 2012), and Dhh-Cre (Jaegle et al., 2003). The Dhh-Cre allele
was maintained on the male. This mouse line and Nf1+/− mice were
maintained on the C57Bl/6 background for n N 8 generations before use.
All mice were maintained on the C57BL/6J background.
2.12. Genotyping
Nf1 genotyping was performed using the oligonucleotides (all 5′ to
3′) GTATTG AATTGAAGCACCTTTGTT TG and CTGCCCAAGGCTCCCCCAGto detect thewildtype allele, andGCGTGTTCGAATTCGCCAATG to detect
the targeted allele (neo) as described (Brannan et al., 1994). Ink4a/Arf
mice (B6.129-Cdkn2atm1Rdp/NCI) were genotyped according to Mouse
repository MMHCC strain #01XB1; Dhh-Cre Forward primer ACCCTGT
TACGTATA GCCGA and 5′ CTCCGGTATTGA AACTCCAG; Meis1 Flox
primers CCAAAGTAGCCACCAATA TCATGA and AGCGTCACTTGGA
AAAGCAATGAT.
3. Results
3.1. MPNST cell survival is dependent on multiple overexpressed genes
Weused a gene expression data set consisting of samples of primary
neuroﬁbroma Schwann cells, neuroﬁbromas, MPNST cell lines and pri-
mary MPNST, compared to normal human Schwann cells (Miller et al.,
2009). Expression levels were normalized to those of Schwann cells
for each gene, because, of the tumor cell types in benign neuroﬁbromas
(Schwann cells, endothelial cells, ﬁbroblasts, macrophages and mast
cells), only neural crest-derived Schwann cells show biallelic mutations
in theNF1 gene (Serra et al., 2000).We approached the identiﬁcation of
unique driver genes by focusing on genes in the C10/C11 K-means clus-
ters; these clusters identify genes with increased expression in neuroﬁ-
broma and also in MPNST (Fig. 1A). We hypothesized that some these
130 genes would be essential to MPNST cell growth.
A lentiviral shRNA library was used to downregulate each of the130
genes over-expressed N3 fold. This library included 3–5 shRNAper gene
(a total of 593 individual lentiviruses; Supplemental Table 1). ShSOX9, a
known inhibitor of MPNST cell growth, was used as a positive control
(Miller et al., 2009). A non-targeting shRNA (shNT) lentivirus was
used as a negative control. A primary screen on a single NF1 mutant
MPNST cell line (T265) identiﬁed 100 genes for which at least 2 shRNAs
caused signiﬁcant (NshSOX9) adverse effects on MPNST cell growth
(Fig. 1B, C). Thus, Screen I showed that a remarkable number of shRNAs
targeting overexpressed genes compromised MPNST cell growth. In
Screen II, a screen of 42/127 randomly selected genes (shRNAs on 2 of
7 96-well plates containing virus) were tested in the additional
MPNST cell lines 8814 (NF1−/−), S462TY (NF1−/−) and STS26T (sporad-
ic MPNST wild-type for NF1; Supplemental Table 2); results for each
shRNA were generally comparable among cell lines.
To exclude shRNAs that compromisedMPNST cell growth due to off-
target effects or through effects downstreamof thewell-studied RAS ac-
tivation inMPNST cells, we infected an A549 lung adenocarcinoma cells
with the same set of shRNAs (Screen III). A549 cells have an activating
mutation in the K-Ras gene (Rodenhuis et al., 1987). They differ from
MPNST cells in terms of lineage; MPNST cells are neural crest derived,
while A549 cells are derived from ectoderm. We did this screen to ex-
clude genes commonly induced by Ras activation, and to identify
genes related to MPNST cell lineage.
Only 7 of the 100 genes affectingMPNST cell growth showed little
effect on A549 cells (Fig. 1D; boxed yellow square). All 7 were
targeted by at least 2 shRNAs, inhibited growth of MPNST cells by
N50%, but inhibited A549 cells by b25% (Fig. 1E). A heatmap shows
the expression of these 7 genes in benign neuroﬁbromas and
MPNSTs versus normal human Schwann cells (Fig. 1F). We decided
to focus on MEIS1 because it acts as an oncogene in leukemia
(Kumar et al., 2009, 2010, Nakamura et al., 1996), yet is poorly stud-
ied in other settings.
3.2. MEIS1 is overexpressed in human tumors and MPNST cell lines
MEIS1 mRNA expression progressively increases in neuroﬁbroma
Schwann cells, neuroﬁbroma, MPNST and MPNST cell lines. Its expres-
sion level varies among individual samples in each group (Fig. 2A).
Using anti-MEIS1 antibody in immunohistochemistry we veriﬁed ex-
pression of MEIS1 protein in 9/9 MPNST solid tumors. Positive labelling
for MEIS1 was of similar intensity in all labeled cells. However, the
Fig. 1. (A) K-means clustering of transcripts with increased expression in dermal neuroﬁbroma Schwann cells (dNFSC), plexiform neuroﬁbroma Schwann cell (pNFSC), dermal
neuroﬁbroma tumors (dNF), plexiform neuroﬁbroma tumors (pNF), MPNST cell lines and MPNST solid tumors versus normal human Schwann cells (NHSC). The bar to the right of the
heat map shows ﬁve k-means functional clusters (C6–C11). Genes overexpressed in neuroﬁbroma and MPNST samples cluster in C10–C11. (B) A schematic representation of medium
throughput shRNA screen targeting genes overexpressed N3 fold in MPNSTs versus normal human Schwann cells. Each tested shRNA was used to infect cells in triplicate wells of a 96
well plate. Cell viability was measured for each well. Data is shown as the average of 3 wells. (C) Survival data from Screen I represented as a bar graph with cell growth measured in
an MTS assay. Green vertical bar represents survival of MPNST with shNT; red vertical bar represents survival effects of shSOX9. Yellow horizontal bar represents cut off to select
shRNAs showing detrimental effect on survival. (D) Screen II data shown in a dot plot. The percent survival of MPNSTs (T265) versus shNT is represented on the y axis, and the same
statistic for lung adenocarcinoma (A549) is on the x axis. The yellow box encloses points representing shRNAs affecting MPNST cell survival N50% but less effect on A549 cells. (E) Bar
graph depicting survival for two shRNAs/gene (a,b) in the yellow box from D. (F) Expression data from panel A showing the 7 genes identiﬁed as speciﬁc to MPNST but not A549 cells.
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single nucleotide polymorphisms (SNP) data revealedMEIS1 locus am-
pliﬁcation in 6/35 (17.1%) of sporadic and in 6/16 (35.5%) of NF1-asso-
ciated MPNSTs (Fig. 2C, Supplemental Table 3). Supplemental Fig. 2
shows SNP analysis of individual human MPNST, 4 of which show am-
pliﬁcation and 4 of which do not. Overexpression of genes can also be
linked to hypo-methylation. The MEIS1 locus on human chromosome
2 was identiﬁed as hypomethylated in MPNST (Table 1). In vitro, 4/4
human MPNST cell lines conﬁrmed overexpression of MEIS1 at the
mRNA and protein levels, versus iHSC (Fig. 2D, E).Fig. 2. MEIS1 expression is elevated in human MPNSTs. (A) Violin plot of MEIS1 gene expr
Abbreviations = dermal neuroﬁbroma Schwann cells (dNFSC), plexiform neuroﬁbroma Schw
(pNF), MPNST cell lines and MPNST solid tumors versus normal human Schwann cells (NHS
with hematoxylin (blue); scale bar, 100 μm. (C) A bar graph displays gene ampliﬁcation
normalized to iHSCs forMPNST cell lines (S462TY, T265, 8814, STS26T; p b 0.001 by ANOVA: sin3.3. MPNST growth is sensitive to MEIS1 inhibition
Screen I identiﬁed MEIS1 as necessary for survival of MPNSTs. We
studied the effect of twoMEIS1- shRNAs in detail. ShRNAs 33 and 77 de-
creasedMEIS1mRNA expression (5.1 and 6.3 fold, respectively; Fig. 3A).
Inhibiting MEIS1 expression with either shRNA diminished expression
of MEIS1 protein by day 4 after lentiviral infection (Fig. 3B). Both
shRNAs reducedMPNST cell growth relative to shNT controls beginning
after day 3 (Fig.3C); this effect was more pronounced by day 6. These
growth effects were conﬁrmed in 3 additional MPNST cell linesession data in each of seven sample types, normalized to expression in Schwann cells.
ann cell (pNFSC), dermal neuroﬁbroma tumors (dNF), plexiform neuroﬁbroma tumors
C). (B) Representative anti-MEIS1 staining visualized with DAB (brown) counterstained
data of NF related MPNST and Sporadic MPNST. (D) Bar graph depicts MEIS1 mRNA
gle factor). (E) Immunoblot shows elevatedMEIS1 protein isMPNST cell lines versus iHSC.
Table 1
Methylation analysis of the MEIS1 gene locus for 10 MPNST tumor samples from 9 patients as compared to normal human Schwann cells.
UCSC ID Symbol CHR Strand Gene start (TSS) The nearest CpG-IS from TSS Distance between
CpG-IS to TSS (bp)
Methylation status
uc002sdu.1 MEIS1 chr2 + 66516035 66653395 66515842 66517842 193 Hypo
uc002sdv.1 MEIS1 chr2 + 66518311 66653395 66515842 66517842 469 Hypo
uc002sdw.1 MEIS1 chr2 + 66520766 66649781 66515842 66517842 2942 Hypo
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icantly lower levels than MPNST cells, and down regulation of MEIS1
using lentiviral shRNA did not signiﬁcantly affect iHSC or A549 cells
(Fig. 3D, E). Thus, MEIS1knockdown inhibits MPNST cell survival
while human Schwann cells are not signiﬁcantly affected.
In addition to effects on targeted genes, shRNAs can have off-target
effects. To control for possible off-target effects, we generated a lentivi-
rus encoding mouseMeis1 tagged with red ﬂuorescent protein (pCDH-
Meis1-RFP). MPNST cells infected with this virus expressed Meis1-RFP,
which did not interfere with cell growth. Cells infected withMeis1-RFP
alone did not survive puromycin selection, while puromycin-resistant
cells infected with shMEIS1 alone die due to downregulation ofMEIS1
expression (schematic in Fig. 3F). Simultaneous infection of MPNST
cells with shMEIS1 and pCDH-Meis1-RFP rescued MPNST survival as
assessed by visualization and quantiﬁed by MTS assay (Fig. 3G–I).
Thus, shMEIS1 effects onMPNST cell survival are speciﬁc to knockdown
of MEIS1. Overexpression of Meis1 in iHSC that are wildtype at the NF1Fig. 3. Reducing MEIS1 expression in MPNST cells (S462TY) inhibits cell growth. (A) Bar graph
Western blot shows that MEIS1 protein expression is reduced by day 4 post infection (p.i.4) wi
MPNST growth after transduction with shMEIS1 or shNT control at days 1, 3 and 6 in an MTS as
cells than in iHSC or A549 cells. (E) Bar graph depicts the increased effects of shMEIS1 on M
speciﬁcity of shMEIS1, using a mouse Meis1-RFP protein and a human-targeting shMEIS1. (G
OE and shMEIS1 versus vector (Empty-RFP) with shMEIS1. (H) Fluorescent (red, left) imag
shMEIS1. (I) Bar graph quantiﬁes cell survival in MTS assays conducted day 3 or 6 after infectilocus, or iHSC infected with shNF1 did not result in transformation of
these cells as tested in a soft agar assay (not shown), suggesting that
overexpression of Meis1 is not sufﬁcient for transformation in this
setting.
3.4. Meis1 downregulation attenuates tumor burden in an MPSNT mouse
model
The shRNA screening described above tested if acute downregula-
tion of MEIS1 is essential for cell survival in human cell lines. To test if
loss of Meis1 affects MPNST growth in primary tumors with an intact
microenvironment, we developed a genetically engineered mouse
model. We used the Ink4a/Arf−/−;Nf1+/− GEM-PNST mouse model
that recapitulates mutations in human MPNSTs. A quarter of these
mice form GEM-PNST (Joseph et al., 2008). Since whole bodyMeis1 de-
letion is embryonically lethal, we bred Ink4a/Arf−/−;Nf1+/−withMeis1f/
f mice, and with Dhh-Cre-mice, which express Cre-recombinaseshows that shMEIS1 (shRNA#33 or #77) reduceMEIS1mRNA in MPNST, by qRT-PCR. (B)
th both shMEIS1 viruses. Anti-β-actin was used as a loading control. (C) Line graph depicts
say (p b 0.001). (D) An immunoblot shows that MEIS1 protein levels are higher inMPNST
PNST compared to iHSC or A549. (F) Schematic shows experiment designed to test the
) Immunoblot shows Meis1 protein expression in MPNST cells infected with Meis1-RFP
es show rescue of cells expressing Meis1-RFP OE and shMEIS1 versus Empty-RFP and
on. (p b 0.001 via ANOVA: single factor).
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neural crest cells known as Schwann cell precursors (Wu et al., 2008).
Nf1+/−;Ink4a/Arf−/−;Meis1f/f;DhhCre+ and littermate controls were
followed for tumor formation. Nf1+/−;Ink4a/Arf−/−mice withMeis1f/f
or Dhh-Cre alleles alone died by 10 months of age, as previously de-
scribed for the Nf1+/−;Ink4a/Arf−/− model (Fig. 4A). GEM-PNSTs in
these animals are grossly evident, typically at 4–6 months of age on
the shoulders, ribs, or limbs of mice, in the vicinity of peripheral nerves.
Importantly, signiﬁcantly fewer GEM-PNSTs were observed in Nf1+/−
;Ink4a/Arf−/−;Meis1f/f;DhhCre+ mice, where Meis1 deletion was re-
stricted to the glial cells arising from Schwann cell precursors (Fig.
4B), as compared to Nf1+/−;Ink4a/Arf−/− mice. Hematopoietic neo-
plasms also develop in Nf1+/−;Ink4a/Arf−/− mice, as described by Jo-
seph et al. Occurrence of hematopoietic neoplasms was not reduced
with Meis1 loss in nerve glial cells. Both Nf1+/−;Ink4a/Arf−/− and
Nf1+/−;Ink4a/Arf−/−;Meis1f/f;DhhCre+ mice succumbed to hematopoi-
etic malignancies, with enlarged liver and/or spleen (Fig. 4B). The pro-
portion of hematopoietic malignancies (44%) observed in Nf1+/−
;Ink4a/Arf−/− mice was similar to that described in the previous
report (Joseph et al., 2008). Hematopoietic malignancies typically
occur in 6–8 month old Nf1+/−;Ink4a/Arf−/−mice. Nf1+/−;Ink4a/Arf−/−
;Meis1f/f;DhhCre+ mice that failed to develop GEM-PNST developed he-
matopoietic disease, as read out by increase liver/spleen size (66%;
Fig. 4B). Some mice with GEM-PNST might also have had sub-clinical
hematopoietic disease that could be revealed by additional analysis.
Histological analysis of MPNST-like tumors conﬁrmed features typi-
cal of mouse GEM-PNST (Stemmer-Rachamimov et al., 2004), with
scattered cells expressing the Schwann cell marker S100 (Supplemental
Fig. 3A), nerve bundles (Supplemental Fig. 3C) positive for neuroﬁla-
ment staining (Supplemental Fig. 3C inset), and frequent regions of
hemorrhage (Supplemental Fig. 3D). Cells often showed fascicular
growth patterns with tightly packed spindle cells (Supplemental Fig.
3E, inset). Cells showed hyperchromatic nuclei and frequent mitoses
(Fig. 4J). Two of 27 mice in the Nf1+/−;Ink4a/Arf−/−;Meis1f/f;DhhCre+
cohort developed GEM-PNST. While wild type mouse sciatic nerve did
not show Meis1 expression (not shown), both these tumors stained
positive for Meis1 (Supplemental Fig. 3), suggesting that they devel-
oped in nerve glial cells that had escaped inactivation ofMeis1. Indeed,
Dhh-Cre targets only about 50% of nerve glial cells (Wu et al., 2008).
These results demonstrate an essential role for Meis1 in driving GEM-
PNST, and conﬁrm that Meis1 is an MPNST oncogene.
3.5. Downregulation of MEIS1 disrupts normal cycling of MPSNT cells in
vitro
We studied cell cycle dynamics to understand the mechanisms of
growth inhibition after MEIS1 down regulation (Fig. 5A). HumanFig. 4.Genetic deletion ofMeis1 prevents formation of GEM-PNST. (A) Kaplan-Meier survival an
increased by Meis1 deﬁciency (p = 0.00024; log-rank Mantel-Cox test). (B) Bar graph show
neoplasms. All mice were assessed at time of death for tumors and hematopoietic neoplas
(C) Agarose gel shows that mouse sciatic nerve fromMeis1-ﬂoxmice with Dhh-Cre contain cel
deletedMeis1 allele.MPNST cells transduced with shMEIS1 were analyzed 4.5 days post in-
fection by ﬂow cytometry. Apoptotic cells (AnnexinV+) were also
stained with propidium iodide, marking DNA. This analysis revealed a
3.7 fold increase in apoptotic cells in shMEIS1 samples (Fig. 5B). In addi-
tion, MEIS1 downregulation increased numbers of MPNST cells in the
G1/G0 phase of the cell cycle (20% increase versus shNT), and a dramatic
depletion of cells in S phase (70% decrease versus shNT) (Fig. 5C). These
results suggest an arrest in proliferation upon downregulation ofMEIS1
expression. This interpretation was conﬁrmed by analysis of cycle regu-
lator proteins. The decrease in S phase upon downregulation ofMEIS1
expression correlated with increased levels of the cell cycle inhibitor
p27Kip (Fig. 5D). Cyclin E2 and cyclin D1, markers of the late G1 phase
of the cell cycle, were decreased. This correlated with hypo-phosphory-
lation of Rb,which is required for transition fromG1 to S in normally cy-
cling cells (Giacinti and Giordano, 2006). Increased cleaved PARP levels
conﬁrmed apoptotic cell death (Fig. 5D). Together, these data indicate
that reduced proliferation is accompanied by increased cell death in
MPNST uponMEIS1 downregulation.
3.6. MEIS1 drives proliferation of MPNSTs via inhibition of p27Kip
To deﬁne molecular pathways regulated by MEIS1 in MPNST cells,
we compared the gene-expression proﬁles of shMEIS1 and shNT treated
cells. We selected transduced MPNST cells in puromycin and analyzed
RNA proﬁles by Affymetrix whole genome arrays at day 3.5 after infec-
tion, before cells had begun to die. Gene-set enrichment analysis re-
vealed signiﬁcant alterations in cell cycle genes, supporting our cell
cycle analyses (Table 2). Interestingly, Inhibitor of DNA Binding 1
(ID1) and Cyclin E2 (CCNE2) were downregulated by shMEIS1 (Fig.
6A), and were in a subset of genes that we deﬁned as being downregu-
lated by shMEIS1 and containing predicted MEIS1 binding sites within
10 kb up- or down- stream of their transcriptional start sites. Differen-
tial expression of these two genes was validated using qRT-PCR (Sup-
plemental Fig. 1C). ID1 can downregulate the cell cycle inhibitor
p27Kip, which has roles in the G1/S transition (Ling et al., 2002;
Manrique et al., 2015). Given the observed proliferation block after
MEIS1 knockdown (Fig. 5C) and the concomitant ID1 and CCNE2 down-
regulation, we hypothesized that ID1 and/or CCNE2 might be critical
mediators of the growth effects of MEIS1. We performed knockdown
of ID1 and CCNE2 (Supplemental Fig. 1D) using lentiviral shRNAs to
test if downregulation of either ID1 or CCNE2 causes MPNST growth ar-
rest. Down regulation of CCNE2 resulted in minimal effects on MPNST
growth (Fig. 6B, C). Importantly, however, downregulation of ID1mim-
icked downregulation of MEIS1, and signiﬁcantly inhibited growth of
MPNST (Fig. 6C). In addition, like knockdown ofMEIS1, knockdown of
ID1 resulted in upregulation of p27kip and apoptosis, as shown by
cleaved PARP (Fig. 6D).alysis shows that the lifespan ofNf1+/−;Ink4a/Arf−/−;Meis1f/f;DhhCre+mice is signiﬁcantly
s the percent of mice in each cohort that succumbed to MPNSTs versus hematopoietic
ms represented by enlarged liver/spleen. Mouse found dead did not show GEM-PNST.
ls withMeis1 deletion. The 440 bp band is the ﬂoxed Meis1 allele; the 260 bp band is the
Fig. 5.Downregulation of MEIS1 causesMPNSTs cell cycle arrest in G1 and cell death. (A) Phase contrast images show fewer cells on plates infected with shMEIS1 versus shNT day 6 post
infections. (B) Flow cytometry data for PI andAnnexinV stained S462-TY cells transducedwith shControl or shMEIS1 4.5 days p.i. (C)Histogramdisplays data from ﬂow cytometry analysis
using theDNAdye propidium iodide (P.I.) showing the cell cycle phases includingG1, S andG2. ShMEIS1 treated samples (red line) show fewer cells in S-phase and a signiﬁcant increase in
percent dead cells versus untreated (UN) or shNT infected cells all at post infection day 4.5. (D) Immunoblots show levels of cell cycle proteins p27Kip, phospho-Rb at designated
phosphorylation sites, cyclinE2 and cyclinD1cell p.i day 5 in UN, shNT and shMEIS1 MPNST cells. Cleaved PARP marks cell death. Anti-β-actin was used as a loading control.
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on downregulation of MEIS1. Remarkably shCDKN1B (CDKN1B encodes
the p27Kip protein) completely prevented shMEIS1 effects on MPNSTs
cells (Fig. 6E, F). Immunoblots conﬁrmed the successful downregulation
of MEIS1 and p27Kip protein expression by the shRNAs (Fig. 6G). Knock-
down of p27Kip was accompanied by a dramatic reduction in cleaved
PARP. Thus, MEIS1 in MPNST cells inhibits p27Kip expression, enabling
cell survival (Fig. 6H).4. Discussion
Our screen for novelMPNST driver genes used data fromneuroﬁbro-
ma and MPNST samples in comparison to Schwann cells (Miller et al.,
2009), themost complete gene expression analysis data currently avail-
able for these tumors, and is a shRNA screen described in cells from this
sarcoma type.We chose to down-regulate genes overexpressed in neu-
roﬁbroma andMPNST. A counter screen in A549 cells resulted in identi-
ﬁcation of genes speciﬁc to MPNST, as well as a list of genes that are
potentially relevant to other cells that dependonRAS signaling (Supple-
mental Fig. 1A). We identify MEIS1, a known leukemia oncogene, as an
oncogenic driver of MPNST. Mechanistically, we found that MEIS1
downregulates the expression of p27Kip, which enables MPNST cell
survival.Table 2
Gene set enrichment analysis using genes with altered expression after shMEISl in MPNST cells
that were identiﬁed using the sources listed.
# ID Name Source
2 920977 RB in cancer BioSystems: Wik
9 105683 Activation of DNA fragmentation factor BioSystems: REAC
3 907939 Tryptophan degradation via kynurenine BioSystems: BIOC
8 105682 Apoptosis induced DNA fragmentation BioSystems: REAC
7 SMP00016 Propanoate metabolism SMPDB
10 106509 Neurophilin interactions with VEGF/VEGFR BioSystems: REAC
13 833812 ECM proteoglycans BioSystems: REAC
14 83064 TGF-beta signaling pathway BioSystems: KEG
15 194384 African trypanosomiasis BioSystems: KEG
18 198828 Hypertrophy model BioSystems: WikRNA interference is a powerful technique used for identiﬁcation of
driver genes in many common cancers. This methodology has pitfalls,
including off-target effects of shRNAs and cellular cytotoxicity
(Reviewed in Cullen, 2006). To minimize these drawbacks, we tested
3–5 shRNA per gene, predicting that they would not share off target ef-
fects. A gene was considered a positive hit only if multiple shRNA/gene
had signiﬁcant effects on cell survival. Supporting the speciﬁcity of
shMEIS1, we reversed the effects by expression of a mouse Meis1
cDNA which was not targeted by the shRNA targeting human MEIS1.
In addition, we recapitulated the effects of shMEIS1 in a loss-of-function
GEMmodel. In contrast to the robust differential expression ofMEIS1 in
MPNST, MEIS3 is not differentially expressed in MPNST cells. MEIS2 is
overexpressed in MPNSTs, and was part of our lentiviral survival
screens. We required that at least two hairpins per gene effectively
blocked growth ofMPNST cells, and did not signiﬁcantly alter A549 sur-
vival to deﬁne a hit. For shMEIS2, only one shRNA blocked MPNST cell
growth, and this shMEIS2 was not speciﬁc to MPNST. Thus, we focused
our efforts on MEIS1.
MEIS1 was the only known oncogene identiﬁed among 7 genes
whose down-regulation diminished survival of MPNST cells. The other
six genes necessary for MPNST but not A549 cell survival await further
study. In a limited analysis, shPITX2 killed iHSC as well as MPNST cells
(not shown). This result indicates that targeting some of the 6 genes,
unlike targeting shMEIS1, causes effects on normal cells. Others of the. We applied an FDR b0.05. The table lists non-redundant pathways identiﬁed at p b 0.002
p-Value # Genes input/#
genes in annotation
Enriched genes p b 0.002
iPathways 1.33E-04 8/87 CCNE2 BARD1 KIF4A HMGB1
MCM3 CDC45 RBBP4 PCNA
TOME 1.31E-03 3/13 HMGB1 HIST1H1C HIST1H1D
YC 5.72E-04 3/10 ID01 KYNII TD02
TOME 1.31E-03 3/13 ACAT1 KYNU TD02
1.02E-03 3/12 ACAT1 ACSS3 PCCB
TOME 1.77E-03 2/4 NRP2 FLT1
TOME 2.63E-03 5/55 ITGA DCN ITGAV LAMA4 LRP4
G 2.68E-03 6/80 ID1 ID3 INHBA DCN FST RBX1
G 2.76E-03 4/34 IL18 ID01 ICAM1 LAMA4
iPathways 4.78E-03 3/20 IL18 NR4A3 IFRD1
Fig. 6. (A) Heat map displays changes in gene after shMEIS1 inMPNST cells versus shNT. (B) Graph shows conﬁrmation of reduced ID1 and CCNE2mRNA inMPNST cells by qRT-PCR after
exposure to respective shRNAs. (C) Survival p.i with shID1, shMEIS1, and shNT, analyzed using an Alamar blue ﬂuorescence assay. (D) Immunoblots show ID1, cleaved PARP, p27Kip and β
Actin in UN, shNT and shID1 treated MPNST cells (p.i. day 4, 6). (E) Phase contrast images show the rescue of cell survival in MPNST cells co-infected with shMEIS1 and shp27, versus
shMEIS1/shNT. (F) Bar graph shows signiﬁcant rescue in survival of MPNST in the presence of shp27. (G) Immunoblots conﬁrm the downregulation of p27Kip expression in cells
infectedwith shp27 concurrent with absence of cleaved PARP. (H) Schematic showing of howMEIS1 is driving survival of MPNST cells through downstream regulation of ID1 and p27Kip.
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our shMEIS1 screen. All 5 cell lines tested, bothNF1 and sporadicMPNST
cells, were sensitive to downregulation of all 7 genes. This ﬁnding is
consistent with the remarkable concordance in gene expression be-
tween NF1 patient and sporadic MPNST cell lines and tumors (Miller
et al., 2006, 2009; Watson et al., 2004). Thus, some or all of the genes
identiﬁed here as necessary for MPNST survival warrant further study.
MEIS1 was expressed in MPNST patient tumors and in MPNST cell
lines. TheMEIS1 locus was ampliﬁed in 23.5% of tested MPNST samples.
MEIS1 is also ampliﬁed in neuroblastoma (Spieker et al., 2001), and up-
regulation of Meis1 is driven by retroviral insertion, causing leukemia
(Nakamura et al., 1996). Methylation analysis of MPNST showed hypo-
methylation, indicating another possible mechanism underlying in-
creasedMEIS1 expression. Given the alterations in PRC complex genes
in MPNST which alter methylation, we postulate that MEIS1 might be
a target of PRC complex effects in some tumors (De Raedt et al., 2014;
Lee et al., 2014). It remains to be determined if additional mechanisms
contribute to MEIS1 over-expression in MPNSTs. In MLL leukemia,
MEIS1 is a direct target of the MLL-fusion protein (Zeisig et al., 2004),
which up-regulates gene-expression by multiple mechanisms, includ-
ing H3K79 methylation and recruiting p-TEFb (Benedikt et al., 2011;
Bernt et al., 2011). In leukemia, and in the developing hematopoietic
system, Meis1 is a Hox co-factor (Penkov et al., 2013, Xiang et al.,
2010). MEIS1 also acts by directly binding DNA. In development, there
is evidence that MEIS1 has direct transcriptional ability (Zhang et al.,
2006; Zhang et al., 2002). MEIS1 is also overexpressed in neuroblasto-
ma, a tumor of neural crest-derived sympathetic cells, likely neuroblasts
(Kiyonari and Kadomatsu, 2015; Geerts et al., 2003). The mechanisms
underlyingMEIS1 up-regulation in neuroblastoma are unknown.
MPNST are believed to be derived from Schwann cell precursors
and/or their neural crest cell precursors, based on expression of neural
crest markers SOX9 and TWIST1 and absence of markers of post-neural
crest Schwann cell precursor cells, including SOX10 (Miller et al., 2009;
Pekmezci et al., 2015; Vogel et al., 1999). We targetedMeis1 deletion in
InkArf−/−;Nf1+/−mice with Dhh-Cre. This Cre driver is not activated in
neural crest cells, but rather in more mature Schwann cell precursor
cells. Therefore, Meis1 deletion in a more mature cell type attenuated
MPNST tumor burden and increased mouse survival. MPNST may arise
from more mature cells which take on characteristics of moreundifferentiated neural crest cells. Alternatively, Meis1 overexpression
may occur subsequent to tumor initiation driven by loss of the Nf1
and Ink/Arf tumor suppressors, and be necessary for tumor promotion.
The latter interpretation is consistent with our ﬁnding that normal
nerve cells do not express detectable Meis1, yet anti-Meis1 staining is
robust in GEM-PNST.
MEIS1 knockdown kills MPNST cells concurrent with a G1 cell cycle
arrest and upregulation of the cell cycle inhibitor p27Kip. p27Kip is essen-
tial for MPNST cell death, as its absence prevents shMEIS1-driven apo-
ptosis (Fig. 6F). This result suggests that cell cycle perturbation due to
deﬁcient MEIS1 drives MPNST cell death. In MLL leukemia stem cells
that depend onMEIS1, p27Kip represses cell proliferation, and enhances
cell quiescence (Zhang et al., 2013).Wewere unable show that prolifer-
ation arrest precedes death, however, in spite of analyzing cells at 12 h
intervals after lentiviral infection (unpublished). Rather, it appears that
G1/S arrest and apoptotic cell death occur concurrently, at least in the
unsynchronized population analyzed. The absence of putative MEIS1
binding sites on p27Kip suggests that MEIS1 regulates CDKN1B (p27Kip)
indirectly, although new MEIS binding sites are still being identiﬁed
(Dardaei et al., 2015). In contrast, however, we identiﬁed 6
NNTGACAGNN and 2 TGACAGNY putative Meis1 binding sites within
10 kb of the ID1 transcriptional start site, although we note that none
were within 2 kb of the transcriptional start site. Which of these sites
(if any) is directly regulated by MEIS1 remains to be determined, and
it remains possible that MEIS1 regulates ID1 indirectly. Regardless, ID1
is likely involved in regulation p27Kip. ID1 can affect tumor growth, in-
vasiveness, and angiogenesis (Ruzinova and Benezra, 2003; Yokota
andMori, 2002). As inMPNST cells, in leukemia, breast cancer and pros-
tate cancer, down-regulation of ID1 leads to increased p27 Kip expres-
sion (Ling et al., 2002; Mern et al., 2010; Ouyang et al., 2002; Sharma
et al., 2012; Tam et al., 2008). In support of a MEIS1, ID1, p27Kip survival
pathway in MPNST, shMEIS1 downregulated ID1, and shID1, like
shMEIS1, killed MPNST cells and increased levels of p27Kip (Fig. 6C, D).
Thus, we postulate that MEIS1 regulates ID1 transcriptionally and that
ID1, in turn, regulates expression of p27Kip.
We ﬁnd that by perturbing the normal cycling of MPNST cells with
shMEIS1, we render them highly sensitive to cell death, in comparison
to iHSC which grow at a similar rate, or in comparison to A549 cells.
Therefore, induction of proliferation arrest in MPNST cells may
118 A.V. Patel et al. / EBioMedicine 9 (2016) 110–119represent a possible therapeutic strategy. Our results identifyMEIS1 as a
transcription factor that drives MPNST cell growth, highlighting the
need for the development of technology which enables successful
targeting of theMEIS1 transcription factor for use in tumors including
leukemia, neuroblastoma, and MPNST.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.06.007.
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